GE HealthCareGEHC
GEHC
About: GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Employees: 53,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
83% more call options, than puts
Call options by funds: $449M | Put options by funds: $245M
68% more first-time investments, than exits
New positions opened: 158 | Existing positions closed: 94
29% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 9 (+2) [Q1 2025]
10% more repeat investments, than reductions
Existing positions increased: 489 | Existing positions reduced: 444
3% more funds holding
Funds holding: 1,297 [Q4 2024] → 1,333 (+36) [Q1 2025]
0% less capital invested
Capital invested by funds: $30.3B [Q4 2024] → $30.2B (-$100M) [Q1 2025]
2.86% less ownership
Funds ownership: 84.66% [Q4 2024] → 81.8% (-2.86%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$73
1%
upside
Avg. target
$83
15%
upside
High target
$89
23%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Morgan Stanley Patrick Wood | 8%upside $78 | Equal-Weight Maintained | 6 May 2025 |
UBS Graham Doyle | 1%upside $73 | Neutral Upgraded | 5 May 2025 |
Goldman Sachs David Roman | 13%upside $82 | Buy Maintained | 1 May 2025 |
Wells Fargo Larry Biegelsen | 23%upside $89 | Overweight Maintained | 1 May 2025 |
Evercore ISI Group Vijay Kumar | 18%upside $85 | Outperform Maintained | 1 May 2025 |
Financial journalist opinion
Based on 5 articles about GEHC published over the past 30 days
Neutral
Business Wire
2 days ago
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare's proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagno.
Positive
Seeking Alpha
1 week ago
GE HealthCare: The Demand Is Just Too Strong To Ignore
GE HealthCare's diverse business model, strong demand, and leadership in key segments position it well for long-term growth, especially with an aging population tailwind. Recent tariff volatility has pressured margins and guidance, but GEHC's global supply chain efficiency and margin recovery potential remain attractive for patient investors. Valuation is compelling at 17x forward PE, with buybacks and robust demand supporting an 18% CAGR outlook to 2029, signaling strong upside potential.
Neutral
The Motley Fool
1 week ago
3 Things Nvidia Management Just Said That Build the Buy Case for These 3 Magnificent Hidden AI Stocks
Nvidia's (NVDA 0.51%) recent earnings report boosted the market and alleviated concerns about any slowdown in artificial intelligence (AI) and data-center-related spending. That's great news for Nvidia and other frontline players in the AI/data center industry.
Neutral
PRNewsWire
1 week ago
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
BOCA RATON, Fla. , June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp.
Positive
Zacks Investment Research
4 weeks ago
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
Positive
Zacks Investment Research
1 month ago
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.
Neutral
Business Wire
1 month ago
GE HealthCare launches CleaRecon DL, introducing AI-based 3D reconstruction to the interventional suite
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of CleaRecon DL, technology powered by a deep-learning algorithm, to improve the quality of cone-beam computed tomography (CBCT) images. This artificial intelligence (AI)-driven solution is designed to remove streak artifacts caused by the pulsatile nature of blood flow in the arteries and changes in the distribution of contrast during CBCT acquisitions in liver, prostate, neuro, and endovascular aortic repair pro.
Positive
Zacks Investment Research
1 month ago
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
Neutral
Business Wire
1 month ago
GE HealthCare Announces FDA Approval of Pediatric Indication for Optison Ultrasound Enhancing Agent
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company's Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart a.
Neutral
Business Wire
1 month ago
GE HealthCare and Raydiant Oximetry accelerate innovation in fetal oxygen saturation technology
CHICAGO & SAN RAMON, Calif.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical decision-making during labor. This effort leverages the combined expertise and technology of the two companies to advance fetal oxygen saturation monitoring technology with the goal of enhancing the detection of fetal distress during childbirth. Incorporating ox.
Charts implemented using Lightweight Charts™